After a delay of several years, people living with multiple sclerosis in England will finally be able to get NHS access to ...

China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder ...

Life sciences equipment and consumable manufacturer Repligen has reached a deal to buy cell therapy specialist BioLife ...

Gilead Sciences and MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral load suppression in ...

Donald Trump has said he intends to impose tariffs of 100% on generic drugs imported into the US from 2028, as part of a ...

Kaken Pharmaceutical has revealed the phase 3 results that supported its recent marketing application for serabelisib in ...

Jonathan Reynolds will lead the new combined Department for Business, Innovation, Science and Trade (DBIST). In the midst of ...

However, while access to this information has never been easier, trust in these resources grows increasingly fragile. Faced ...

Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in ...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Kelly Gold, CFO of CAMP4 Therapeutics, ...

Leela Barham looked at what had happened a year after the NHS 10-Year Plan, released in July 2025, included the commitment to ...

Despite ongoing advancements in genomics, artificial intelligence, and precision medicine, clinical trial success rates have ...